Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Early results of total therapy II in multiple myeloma: implications of cytogenetics and FISH.

Barlogie B Jr, Shaughnessy JD.

Int J Hematol. 2002 Aug;76 Suppl 1:337-9.

PMID:
12430877
2.

Thalidomide in the management of multiple myeloma.

Barlogie B, Tricot G, Anaissie E.

Semin Oncol. 2001 Dec;28(6):577-82. Review.

PMID:
11740812
3.

Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience.

Barlogie B.

Semin Hematol. 2003 Oct;40(4 Suppl 4):33-8. Review.

PMID:
15015894
4.

High-dose therapy and innovative approaches to treatment of multiple myeloma.

Barlogie B.

Semin Hematol. 2001 Apr;38(2 Suppl 3):21-7. Review.

PMID:
11309705
5.

[Intensive treatment of multiple myeloma].

Harousseau JL.

Bull Acad Natl Med. 2003;187(2):405-13; discussion 413-5. Review. French.

PMID:
14556449
6.

Cytogenetic abnormalities in multiple myeloma.

Fonseca R, Coignet LJ, Dewald GW.

Hematol Oncol Clin North Am. 1999 Dec;13(6):1169-80, viii. Review.

PMID:
10626143
7.

Cytogenetic Alterations in Multiple Myeloma: Prognostic Significance and the Choice of Frontline Therapy.

Stella F, Pedrazzini E, Agazzoni M, Ballester O, Slavutsky I.

Cancer Invest. 2015;33(10):496-504. doi: 10.3109/07357907.2015.1080833. Epub 2015 Oct 27. Review.

PMID:
26506456
8.

Cytogenetics and molecular genetics in multiple myeloma.

Feinman R, Sawyer J, Hardin J, Tricot G.

Hematol Oncol Clin North Am. 1997 Feb;11(1):1-25. Review.

PMID:
9081201
9.

Prognosis in multiple myeloma.

Fonseca R, Greipp PR.

Cancer Treat Res. 1999;99:155-70. Review. No abstract available.

PMID:
9891866

Supplemental Content

Support Center